Search
rdESAT-6
go.drugbank.com/drugs/DB21906ApprovedrdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]
Nandrolone phenpropionate
go.drugbank.com/drugs/DB00984ApprovedIllicitIt is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S.
Fruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalThis approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … Although [bevacizumab] is successful in sustaining target inhibition, mandatory intravenous dosing, immunogenicity, and the potential to induce autoimmune diseases hinder its clinical application.
mRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigational[L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Aminoglutethimide
go.drugbank.com/drugs/DB00357ApprovedWithdrawnAminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. … An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens.
Enfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalThe first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells. … Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake
Anthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47526] It is considered one of the most likely agents to be used in a biological attack. … [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.
Astemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnAstemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Scopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. … [A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigational(i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection. … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.